NASDAQ · INDP
Indaptus Therapeutics, Inc.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
Loading market information…
AMEX · AZTR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Azitra, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Azitra, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$1.13+64.69% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$0.53-$0.01 (-1.26%)
Jasper Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.55% below the high.
$1.46-$0.01 (-0.68%)
Enveric Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.98% below the high.
$0.84+$0.19 (+29.23%)
Salarius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.41% below the high.
$3.75+$0.03 (+0.81%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.76% below the high.
$0.59-$0.01 (-1.99%)
Onconetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.71% below the high.
$0.71-$0.12 (-14.18%)
SciSparc Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.69% below the high.
$0.52-$0.02 (-2.92%)
Scinai Immunotherapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 96.65% below the high.
